Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer 图:PI3K-Akt-mTOR signaling pathway[76] PI3K – Akt还对脂质代谢有影响。PI3K-Akt-信号传导可以通过 S6K1 的信号传导促进SREBP1 活性形式的积累[31, 86]。Akt 介导的 FoxO 抑制减轻会对SREBP-1c的抑制;此外,Akt 对 GSK-3β 的抑制也增强...
摘要 背景:Lineageplasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lungadenocarcinomas(LUADs), this phenomenon includes small cell and squamous cell (LUSC) histologic transformation in the context of acquired resistance to targ...
1Research Institute, National Cancer Center, Goyang, Republic of Korea;2Center for Clinical Trials, National Cancer Center, Goyang, Republic of Korea;3Incurix Co., Ltd., Goyang, Republic of Korea;4Department of Patholog...
1Research Institute, National Cancer Center, Goyang, Republic of Korea;2Center for Clinical Trials, National Cancer Center, Goyang, Republic of Korea;3Incurix Co., Ltd., Goyang, Republic of Korea;4Department of Pathology, National Cancer Center, Goyang, Republic of Korea;5Center for Lung Cancer...
in the regulation of energy metabolism in tumor cells.It may regulate fatty acid oxidation and OXPHOS of tumor cells by regulating the cMyc/PGC-1 pathway.Targeting metabolic pathways for cancer treatment has been investigated as potential preventive or therapeutic methods.This study has important ...
The MYC gene which consists of 3 paralogs, C-MYC, N-MYC and L-MYC, is one of the most frequently deregulated driver genes in human cancer. Because of its high prevalence of deregulation and its causal role in cancer formation, maintenance and progression, targeting MYC is theoretically an ...
characterized by heightened nutrients uptake, enhanced glycolysis and glutaminolysis,and elevated fatty acid and nucleotide synthesis.This paper briefly summarizes how c-Myc regulated metabolism on glycolysis,glutamine metabolism,tricarboxylic acid cycle,lipid metabolism and nucleotide synthesis in cancer cell,...
[9]LI S, FU J, LU C, et al. Elevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myeloma[J]. Mol Cancer Ther, 2016, 15(4):711-719.[10]GARCÍA-GUTIÉRREZ L, DELGADO MD, LEÓN J. MYC on...
Lung cancer is the leading cause of cancer-related mortality, with nonsmall cell lung cancer (NSCLC) the most common subtype (1). Mutations in Kras are found in more than 30% of NSCLC cases, while the RTK/RAS/RAF pathway is activated in 76% of cases (2). In addition, Myc is freque...
Herein, we discuss how MYC pathways not only dictate cancer cell pathophysiology but also suppress the host immune response against that cancer. We also propose that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients ...